Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Sir Patrick Vallance, the UK’s chief scientific adviser, has announced that 40% of people admitted to hospital with COVID in the UK have had two doses of a coronavirus vaccine. At first glance, this rings very serious alarm bells, but it shouldn’t. The vaccines are still working very well.

There are several factors at play that explain why such a high proportion of cases are in the fully vaccinated.

COVID vaccines are extremely effective, but none 100% so. This itself isn’t surprising – flu vaccines aren’t 100% effective either. Yet in the US alone flu vaccines are estimated to prevent millions of cases of illness, tens of thousands of hospitalisations and thousands of deaths every year. The COVID vaccines are doing the same in the UK right now – all one has to do is compare the curves from the winter wave with those from this summer.

Read the full article on The Conversation website, written by Jamie Hartmann-Boyce (Nuffield Department of Primary Care Health Sciences).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.